Trovagene, Inc., Continues to Expand NPM1 Licensing Program for Acute Myelogenous Leukemia

    Trovagene, Inc., Continues to Expand NPM1 Licensing Program for Acute
                             Myelogenous Leukemia

PR Newswire

SAN DIEGO, Dec. 20, 2012

SAN DIEGO, Dec. 20, 2012 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:TROV) today
announced it has granted Genoptix, Inc. (a Novartis Group Company) a
worldwide, non-exclusive license to incorporate nucleophosmin protein (NPM1)
into research and clinical testing services for acute myelogenous leukemia
(AML). Trovagene holds an exclusive worldwide license to US patent 8,222,370
and the corresponding group of U.S. and foreign patent applications around
NPM1. Terms of the agreement include upfront fees and royalty payments.
Additional financial terms were not disclosed.


"Trovagene is pleased to add Genoptix to its list of worldwide licensees of
the NPM1 marker," said Antonius Schuh, Ph.D., chief executive officer for
Trovagene. "Genoptix is one of the leading hematopathology laboratories in
the country, and understands NPM1's value as a prognostic marker for treatment
planning and patient counseling." Testing for NPM1 mutations is recommended by
the National Comprehensive Cancer Network (, which sets clinical
treatment standards for a wide variety of cancers.

Within the United States, Trovagene has granted non-exclusive sublicenses to
offer mutation analysis of NPM1 as a laboratory service for the diagnosis and
monitoring of patients with AML to Quest Diagnostics, LabCorp, Fairview Health
Services and Invivoscribe Technologies; internationally, license holders
include Münchner Leukamielabor GmbH (MLL) in Munich, Germany and Skyline Labs
in the Netherlands. In addition, Trovagene has granted a co-exclusive license
to manufacture and sell NPM1 mutation kits to Asuragen, Inc. and Ipsogen S.A.

Laboratories interested in obtaining a license for testing NPM1 mutations for
AML patients should contact Trovagene directly at 888-391-7992.

About AML

AML is a clinically heterogeneous disease that affects patients worldwide.
About 13,000 new cases per year occur in the U.S., and nearly 9,000 patients
die from the disease annually. Chromosome analysis of leukemia cells provides
valuable prognostic information for physicians treating AML patients.
Mutations involving the NPM1 gene are the most frequent molecular alteration
in AML patients with normal chromosomes, accounting for nearly one-third of
adult AML cases. AML patients with isolated NPM1 mutations have been shown to
have better responses to induction chemotherapy and amore favorable overall

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented
technology for the detection of transrenal DNA and RNA, short nucleic acid
fragments, originating from normal and diseased cell death that cross the
kidney barrier and can be detected in urine. Trovagene is leveraging its
intellectual property in oncogene mutations via out-licensing and use of its
transrenal technologies to extend oncogene mutation detection using urine as a
sample. As a non-invasive and abundant sample, urine may overcome many of the
cost and collection challenges associated with biopsy, as well as the volume
limitations of blood.

Trovagene has a strong patent position as it relates to transrenal molecular
testing. It has U.S. and European patent applications and issued patents that
cover testing for HPV and other infectious diseases, cancer, transplantation,
prenatal and genetic testing. In addition, it owns worldwide rights to
nucleophosmin-1 (NPM1), an informative biomarker for acute myelogenous
leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be
associated with chemotherapy response in chronic lymphocytic leukemia (CLL)
patients, as well as other hematologic malignancies.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend," among others.
These forward-looking statements are based on Trovagene's current expectations
and actual results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to,
substantial competition; our ability to continue as a going concern; our need
for additional financing; uncertainties of patent protection and litigation;
uncertainties of government or third party payer reimbursement; limited sales
and marketing efforts and dependence upon third parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance with FDA
regulations. As with any medical diagnostic tests under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. There are no guarantees that future
clinical trials discussed in this press release will be completed or
successful or that any product will receive regulatory approval for any
indication or prove to be commercially successful. Trovagene does not
undertake an obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in Trovagene's Form 10-K for
the year ended December 31, 2011 and other periodic reports filed with the
Securities and Exchange Commission.

Trovagene, Inc.
Michael Terry
VP, Corporate Development
+1 (858) 952-7641

SOURCE Trovagene, Inc.

Press spacebar to pause and continue. Press esc to stop.